Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study-Reference-Cited by-同舟云学术

Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study

Published:2020-01 Issue:1 Volume:55 Page:105836
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Kyriazopoulou Evdoxia^ORCID,Sinapidis Dimitrios,Halvatzis Stamatios,Velissaris Dimitrios,Alexiou Nikolaos,Kosmas Vasilios,Adami Maria-Evangelia,Kyprianou Miltiades,Kyprianou Aikaterini,Stefos Aggelos,Lada Malvina^ORCID,Koutoukas Pantelis,Pavlaki Maria,Kyriakoudi Anna,Makina Anna,Gogos Charalambos,Niederman Michael S.,Giamarellos-Bourboulis Evangelos J.^ORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference24 articles.

1. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone;García Vázquez;Eur J Clin Microbiol Infect Dis,2005

2. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized veterans affairs patients with community-acquired pneumonia;Lodise;Antimicrob Agents Chemother,2007

3. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia;Martínez;Clin Infect Dis,2003

4. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones;Metersky;Chest,2007

5. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia;Restrepo;Eur Respir J,2009

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of De-Escalation of Empirical Antimicrobial Therapy in Medical Wards with Recognized Prevalence of Multi-Drug-Resistant Pathogens: A Multicenter Prospective Cohort Study in Non-ICU Patients with Microbiologically Documented Infection;Antibiotics;2024-08-27

2. In community-acquired pneumonia, adding oral clarithromycin to standard care increased early clinical response;Annals of Internal Medicine;2024-05

3. Ergänzendes Makrolid bessert klinisches Ansprechen und Inflammationslast;Pneumo News;2024-04-26

4. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial;The Lancet Respiratory Medicine;2024-04

5. Efficacy and safety of clarithromycin for patients with sepsis or septic shock: a systematic review and meta-analysis;Emergency and Critical Care Medicine;2023-11-26